CoDiagnostics, based in Salt Lake City, develops molecular tools for infectious disease detection, cancer screening, and agriculture, employing 155 staff. The company went public in July 2017 and is creating a portable diagnostic system for at-home use.
CODX has been in the news recently: Co-Diagnostics, Inc. has been granted its first Australian patent for the Co-Dx PCR platform, which improves its capabilities for decentralized molecular testing. Additionally, the company plans to execute a 1-for-30 reverse stock split on January 2, 2026, to comply with Nasdaq's minimum bid price requirement of $1.00.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.